| Filed On | Filing |
|---|---|
| 01 Sep 2026 | TOTAL VOTING RIGHTS |
| 01 Sep 2026 | MRNA FLU VACCINE CANDIDATE TO ADVANCE TO PHASE III |
| 26 Aug 2026 | DIRECTOR/PDMR SHAREHOLDING |
| 24 Aug 2026 | DIRECTOR/PDMR SHAREHOLDING |
| 24 Aug 2026 | US FDA TO REVIEW JEMPERLI FOR RECTAL CANCER |
| 24 Aug 2026 | FIRST GLOBAL APPROVAL FOR HIBSAGO IN JAPAN |
| 20 Aug 2026 | 144 |
| 18 Aug 2026 | DIRECTOR/PDMR SHAREHOLDING |
| 13 Aug 2026 | DIRECTOR/PDMR SHAREHOLDING |
| 13 Aug 2026 | 13F-HR |
| 13 Aug 2026 | SCHEDULE 13G/A |
| 11 Aug 2026 | DIRECTOR/PDMR SHAREHOLDING |
| 03 Aug 2026 | TOTAL VOTING RIGHTS |
| 30 Jul 2026 | DIRECTOR/PDMR SHAREHOLDING |
| 28 Jul 2026 | 2ND QUARTER RESULTS |
| 28 Jul 2026 | HANSOH POSITIVE 2ND PHASE III RESULTS FOR RIZ-REZ |
| 28 Jul 2026 | NEW GSK FLAGSHIP R&D CENTRE IN CAMBRIDGE |
| 24 Jul 2026 | DIRECTOR/PDMR SHAREHOLDING |
| 24 Jul 2026 | ADMISSION TO TRADING |
| 22 Jul 2026 | JIDEYTRO APPROVED IN US FOR CERTAIN LUNG CANCERS |
Loading...
